Matinas BioPharma Hldgs
(AMEX:MTNB)
$0.2725
0[0.00%]
At close: Mar 18

GET A REPORT ON MTNB SENT RIGHT TO YOUR INBOX

Matinas BioPharma Hldgs Stock (AMEX:MTNB), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.
Consensus Rating1
Buy
Highest Price Target1
$3.00
Lowest Price Target1
$3.00
Consensus Price Target1
$3.00

Analyst Rating Summary1

Analyst Ratings
Oct 23
1
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

BTIG
HC Wainwright & Co.

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Matinas BioPharma Hldgs

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
10/11/2023MTNBBuy Now
Matinas BioPharma Hldgs
$0.271001.32%BTIG
Julian Harrison
$3 → $3ReinstatesBuy → BuyGet Alert
01/31/2023MTNBBuy Now
Matinas BioPharma Hldgs
$0.271001.32%HC Wainwright & Co.
Andrew Fein
→ $3Reiterates → BuyGet Alert

FAQ

Q

What is the target price for Matinas BioPharma Hldgs (MTNB)?

A

The latest price target for Matinas BioPharma Hldgs (AMEX: MTNB) was reported by BTIG on October 11, 2023. The analyst firm set a price target for $3.00 expecting MTNB to rise to within 12 months (a possible 1000.92% upside). 1 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Matinas BioPharma Hldgs (MTNB)?

A

The latest analyst rating for Matinas BioPharma Hldgs (AMEX: MTNB) was provided by BTIG, and Matinas BioPharma Hldgs their buy rating.

Q

When is the next analyst rating going to be posted or updated for Matinas BioPharma Hldgs (MTNB)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Matinas BioPharma Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Matinas BioPharma Hldgs was filed on October 11, 2023 so you should expect the next rating to be made available sometime around October 11, 2024.

Q

Is the Analyst Rating Matinas BioPharma Hldgs (MTNB) correct?

A

While ratings are subjective and will change, the latest Matinas BioPharma Hldgs (MTNB) rating was a with a price target of $3.00 to $3.00. The current price Matinas BioPharma Hldgs (MTNB) is trading at is $0.27, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.